You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for HYDROCODONE-CHLORPHEN ER SUSP


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HYDROCODONE-CHLORPHEN ER SUSP

Average Pharmacy Cost for HYDROCODONE-CHLORPHEN ER SUSP

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-01 0.42835 ML 2025-01-22
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-02 0.29194 ML 2025-01-22
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-01 0.40618 ML 2024-12-18
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-02 0.31700 ML 2024-12-18
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-01 0.41434 ML 2024-11-20
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-02 0.28044 ML 2024-11-20
HYDROCODONE-CHLORPHEN ER SUSP 27808-0086-02 0.39399 ML 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Hydrocodone-Chlorpheniramine Extended Release Suspension

Introduction

Hydrocodone-chlorpheniramine extended release suspension, commonly used for treating cold symptoms and cough, is a combination drug that has been under scrutiny due to its opioid component and associated risks. Here, we will delve into the market analysis and price projections for this medication.

Market Overview

The hydrocodone-chlorpheniramine combination is part of the upper respiratory combinations drug class. This class has seen significant usage over the years, particularly for managing symptoms of colds and coughs.

Usage Trends

The usage of hydrocodone-chlorpheniramine has been influenced by safety concerns, especially in pediatric populations. A benefit-risk review highlighted that the drug's use in children under 6 years is contraindicated due to the risk of life-threatening respiratory depression[1].

Pricing Dynamics

The pricing of hydrocodone-chlorpheniramine extended release suspension varies based on the formulation, quantity, and pharmacy.

Current Pricing

  • For a 70 milliliter supply of the oral suspension (8 mg-10 mg/5 mL), the cost is approximately $24.09 for cash-paying customers using a discount card[2][5].
  • A larger supply of 115 milliliters costs around $173.02, with the price per unit being $1.50[5].

Discounts and Assistance Programs

Several discount programs, coupons, and copay cards are available to reduce the cost of this medication. For instance, the Drugs.com Discount Card can save consumers up to 80% off the cost of prescription medicines[5].

Market Factors Influencing Pricing

Regulatory Changes

Recent regulatory changes, such as those introduced by the Inflation Reduction Act, are expected to impact prescription drug spending. These changes include provisions for drug price negotiations and inflation rebates, which could lead to a reduction in aggregate drug costs and out-of-pocket spending for consumers[3].

Safety and Efficacy Concerns

The safety profile of hydrocodone-chlorpheniramine, particularly in pediatric patients, has led to a decline in its use. The absence of reported adverse events in pediatric patients since 2011, following labeling changes and the introduction of unit-of-use packaging, suggests that these measures have contributed to safer use practices[1].

Generic Availability

The availability of generic versions of hydrocodone-chlorpheniramine can significantly impact pricing. Generic options are generally cheaper, with prices starting from $24.09 for a 70 milliliter supply, making the medication more accessible to a wider audience[2][5].

Price Projections

Short-Term Projections

In the short term, prices for hydrocodone-chlorpheniramine extended release suspension are likely to remain stable or see minor adjustments based on market demand and competition from generic alternatives.

Long-Term Projections

Long-term price projections suggest that the overall trend in prescription drug spending, including for hydrocodone-chlorpheniramine, will be moderate. The Inflation Reduction Act's provisions are expected to reduce out-of-pocket spending and aggregate drug costs, which could lead to more stable or slightly reduced prices over the next decade[3].

Consumer Impact

Affordability

The affordability of hydrocodone-chlorpheniramine is crucial for consumers, especially those without insurance or with limited financial resources. Discount programs and generic options play a significant role in making this medication more accessible.

Safety Considerations

Consumers must be aware of the potential risks associated with hydrocodone-chlorpheniramine, particularly the risk of opioid addiction, abuse, and overdose. This awareness can influence market demand and pricing as safer alternatives may be sought[4].

Key Takeaways

  • Pricing Stability: Prices for hydrocodone-chlorpheniramine extended release suspension are expected to remain relatively stable in the short term.
  • Generic Impact: The availability of generic versions significantly reduces the cost, making the medication more affordable.
  • Regulatory Influence: Recent regulatory changes are likely to moderate prescription drug spending, including for hydrocodone-chlorpheniramine.
  • Safety Concerns: The drug's safety profile, especially in pediatric patients, continues to be a critical factor in its market dynamics.

FAQs

  1. What is the current price range for hydrocodone-chlorpheniramine extended release suspension?

    • The current price range is approximately $24.09 for a 70 milliliter supply and $173.02 for a 115 milliliter supply[2][5].
  2. Are there any discount programs available for hydrocodone-chlorpheniramine?

    • Yes, several discount programs, coupons, and copay cards are available to reduce the cost of this medication[5].
  3. What are the safety concerns associated with hydrocodone-chlorpheniramine in pediatric patients?

    • The primary safety concern is the risk of life-threatening respiratory depression, particularly in children under 6 years[1].
  4. How do regulatory changes impact the pricing of hydrocodone-chlorpheniramine?

    • Regulatory changes, such as those introduced by the Inflation Reduction Act, are expected to reduce aggregate drug costs and out-of-pocket spending through provisions like drug price negotiations and inflation rebates[3].
  5. Is a generic version of hydrocodone-chlorpheniramine available?

    • Yes, generic versions of hydrocodone-chlorpheniramine are available, which are generally cheaper than the brand-name version[2][5].

Sources

  1. A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine
    • Springer Medizin, 2023.
  2. Chlorpheniramine/hydrocodone Prices, Coupons, Copay Cards & Patient Assistance
    • Drugs.com.
  3. Recent and Forecasted Trends in Prescription Drug Spending
    • Health System Tracker, 2023.
  4. Hydrocodone and Chlorpheniramine | Drug Lookup | Pediatric Care
    • American Academy of Pediatrics.
  5. Tussionex Pennkinetic Prices, Coupons, Copay Cards & Patient Assistance
    • Drugs.com.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.